qualyfast Sars-CoV-2 Variant are one step qPCR kits for the rapid detection of Sars-CoV-2 Variants with RNA Inhibition Control
The introduction and increased diffusion of new SARS-CoV-2 variants first identified in the United Kingdom (B.1.1.7), South Africa (B.1.351) and Brazil (P.1) has raised concerns.Since 21 January 2021, EU/EEA countries have observed a substantial increase in the number and proportion of SARS-CoV-2 cases of the B.1.1.7 variant, first reported in the United Kingdom.
The variant B.1.351 has also been increasingly reported in EU/EEA countries, often, but not only, linked to travel, and it has also been associated with outbreaks. The variant P.1 is so far being reported at lower levels, possibly because it is mainly linked to travel exchange with Brazil, where it appears to be spreading.
The B.1.1.7 variant appears to be more transmissible than the previously predominant circulating strains and may cause more severe infection. Several countries where the variant has become dominant have seen rapid increases in incidence. This has resulted in increased hospitalisations, overstretched health systems and excess mortality. B.1.351 is also associated with increased transmissibility. In addition, there is evidence pointing to the potential for reduced effectiveness for some of the COVID-19 vaccines with this variant.
Rapid detection and discrimination of these SARS-CoV-2 Variants are critical in order to minimize the diffusion of the Variants and to protect people.
qualyfast® Sars-CoV-2 Variant are innovative products for rapid detection and discrimination of UK, South Africa and Brazil Variants in 2 hours. Our Research and development Department guarantees continues update of all the new variants of SARS-CoV-2 and of all the new mutations.